FLT3 and myelodysplastic syndrome: The phase IIB trial of midostaurin for wild‐type or mutated FLT3 AML and high‐risk myelodysplastic syndrome (MDS) showed that the rate of reduction in peripheral blood or bone marrow blasts by ≥50% was 71% in patients with FLT3‐mutant and 42% in patients with FLT3 wild‐type.